E
EDIT
Editas Medicine Inc
1.79
-0.02-1.11%After Hours: 1.730 -0.06 -3.33%19:49 02/20 EST
OPEN/PREV CLOSE1.790/1.810
TODAY RANGE1.720-1.800
VOL1.53M
MARKET CAP174.74M
52 WEEK RANGE0.9101-4.537
AVG VOL (3M)1.69M
% TURNOVER1.57%
TURNOVER--
P/E (TTM)-0.7537
% RANGE4.14%
EPS(TTM)-2.3751
P/E(FORWARD)-0.8796
P/B12.41
BVPS0.1442
DIVIDEND--
P/S4.583
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP174.26M
SHARES OUTSTANDING97.62M
NEXT EARNINGS03/03-03/09
FREE FLOAT97.35M
LOT SIZE1
EX-DATE--
News
Press Releases
Financial Reports
Profile
Simply Wall St·01/23 10:28
Individual investors who hold 55% of Editas Medicine, Inc. (NASDAQ:EDIT) gained 14%, institutions profited as well
TipRanks·01/05 11:56
Editas Medicine (EDIT) Receives a Hold from Wells Fargo
NASDAQ·12/10/2025 16:30
Editas (EDIT) Down 8.3% Since Last Earnings Report: Can It Rebound?
NASDAQ·12/06/2025 11:47
Editas Medicine (EDIT) Price Target Increased by 22.78% to 4.95
NASDAQ·11/27/2025 23:13
Editas (EDIT) Q2 2024 Earnings Call Transcript
NASDAQ·11/25/2025 16:10
NVO Stock Down as Rybelsus Misses Goals in 2 Alzheimer's Studies
NASDAQ·11/25/2025 15:43
Biogen Inks Research Deal With Dayra to Boost Immunology Pipeline
NASDAQ·11/20/2025 16:38
COGT Stock Skyrockets 120% in a Month: Here's What You Need to Know
NASDAQ·11/18/2025 13:48
Top 3 Genomics Stocks to Consider for Your Portfolio
Simply Wall St·11/13/2025 11:26
Analysts Are Upgrading Editas Medicine, Inc. (NASDAQ:EDIT) After Its Latest Results
TipRanks·11/12/2025 22:30
Editas Medicine price target lowered to $3.50 from $12 at Chardan
TipRanks·11/11/2025 21:31
FDA appoints Richard Pazdur as Director of CDER
NASDAQ·11/11/2025 15:37
Editas Q3 Loss Narrower Than Expected, Revenues Increase Y/Y
Same Industry
Name/Symbol
Change%
Price